One To Watch

Insmed

A global biopharmaceutical company headquartered in Bridgewater, New Jersey, dedicated to developing transformative therapies for serious rare diseases, with a commercial portfolio in pulmonary infections and a growing pipeline spanning lung disease, inflammation, and neuromuscular conditions.

Company Overview

Insmed Incorporated is a global biopharmaceutical company focused on the discovery, development, and commercialisation of transformative therapies for patients living with serious and rare diseases. The company has two commercial products — ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex (MAC) lung disease and BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis — and a pipeline spanning pulmonary, inflammatory, and rare neurological diseases. Insmed anticipates at least $1 billion in BRINSUPRI revenues for 2026, representing a substantial commercial inflection point for the company. The company employs more than 1,300 people and operates globally, with a particular focus on North America, Europe, and Japan.

Headquarters and Global Presence

Insmed is headquartered in Bridgewater, New Jersey. The company has established commercial operations in the United States, European Union, United Kingdom, and Japan, with plans to expand BRINSUPRI launches to the EU and Japan in 2026 following regulatory approvals. Manufacturing partnerships with Patheon Inc. and Esteve Química support commercial-scale production of brensocatib globally. Insmed's commercial and medical infrastructure is built around rare pulmonary diseases, enabling targeted physician engagement across specialised pulmonology and respiratory medicine communities. The company maintains international clinical development activities across multiple Phase 2 and Phase 3 programmes.

Founding and History

Insmed was founded in 1988 by Dr. Joseph Larner in Charlottesville, Virginia, initially to develop medicines for metabolic disorders including diabetes. The company's strategic trajectory changed dramatically in 2010 when it acquired Transave Inc., gaining proprietary liposomal drug delivery technology that became the foundation for ARIKAYCE. This acquisition marked a pivot from metabolic research to targeted pulmonary drug development. ARIKAYCE (amikacin liposome inhalation suspension) received FDA approval in September 2018 as the first treatment specifically approved for MAC lung disease, transforming Insmed into a commercial-stage rare disease company. Subsequent approvals in Europe (2020) and Japan (2021) established Insmed as a global rare pulmonary disease organisation. Will Lewis joined as President and CEO in September 2012 and became Board Chair in November 2018.

Therapy Areas and Focus

Insmed's therapeutic focus is centred on rare and serious pulmonary diseases and conditions driven by neutrophil-mediated inflammation. ARIKAYCE addresses MAC lung disease, a serious and progressive non-tuberculous mycobacterial infection primarily affecting people with underlying lung conditions. BRINSUPRI targets non-cystic fibrosis bronchiectasis by inhibiting dipeptidyl peptidase-1 (DPP1), thereby reducing neutrophil elastase activity and breaking the cycle of airway inflammation and infection. Insmed is exploring brensocatib's utility across other neutrophil-driven inflammatory conditions including hidradenitis suppurativa. Beyond pulmonary disease, the company has an emerging neurological pipeline with early-stage gene therapy and antisense oligonucleotide programmes for Duchenne muscular dystrophy, ALS, and Stargardt disease.

Technology Platforms and Modalities

Insmed's scientific platforms span liposomal inhaled drug delivery, DPP1 inhibition, inhaled treprostinil prodrug delivery, gene therapy, and antisense oligonucleotides. ARIKAYCE employs proprietary liposome encapsulation to deliver amikacin directly to infected macrophages in the lung, bypassing systemic toxicity. BRINSUPRI is an oral small molecule DPP1 inhibitor, a first-in-class mechanism for treating bronchiectasis by blocking the activation of neutrophil serine proteases. TPIP (treprostinil palmityl) is an inhaled prodrug of treprostinil being developed for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The neuro pipeline includes an intrathecal gene therapy (ASCEND trial) and INS1202, an antisense oligonucleotide for ALS.

Key Pipeline and Programs

BRINSUPRI is approved in the US and EU for non-cystic fibrosis bronchiectasis, with 2026 launches planned in the EU and Japan; Phase 2b data for brensocatib in hidradenitis suppurativa (CEDAR trial) are expected in Q2 2026. The Phase 3 ENCORE trial of ARIKAYCE in newly diagnosed or recurrent MAC lung disease is expected to report topline data in March or April 2026. TPIP is initiating Phase 3 trials in 2026 across pulmonary arterial hypertension (PAH), pulmonary hypertension with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF). The neurological pipeline includes the Phase 1 ASCEND gene therapy trial for Duchenne muscular dystrophy and the Phase 1 ARMOR study of INS1202 for ALS, with an IND filing for a Stargardt disease programme planned in 2026.

Key Personnel

William H. Lewis, J.D., MBA, serves as Board Chair and Chief Executive Officer, having led Insmed since September 2012, orchestrating the company's strategic transformation from a metabolic disease company to a rare pulmonary disease leader. Under his leadership, Insmed secured the approvals of ARIKAYCE and BRINSUPRI and built a substantial global commercial infrastructure. The board of directors includes lead independent director David R. Brennan, former CEO of AstraZeneca. Sara M. Bonstein serves as Senior Vice President, Portfolio Strategy and Operational Excellence. The scientific and medical leadership team oversees a multi-stage pipeline across rare pulmonary, inflammatory, and neurological programmes.

Strategic Partnerships

Insmed's primary manufacturing partnerships are with Patheon Inc. and Esteve Química, S.A. for the commercial production of brensocatib and BRINSUPRI tablets. The company has agreements with regional distribution partners to support the rollout of BRINSUPRI across EU member states following the European Commission approval in November 2025. Insmed is exploring commercial and development collaborations in China as part of its global expansion strategy. The company's approach to external partnerships in research and development is aligned with its rare disease focus, seeking complementary technology platforms and development capabilities. The January 2026 commercial launch planning for multiple international markets is supported by healthcare provider partnerships and market access agreements across targeted geographies.

FAQ Section

Insmed's central strategic challenge is successfully scaling the global commercial launch of BRINSUPRI across the EU, UK, and Japan in 2026 while achieving or exceeding its ambitious $1 billion revenue target, which would validate the company's position as a significant rare pulmonary disease enterprise and support ongoing investment in its diversified pipeline.

DPP1 activates neutrophil serine proteases in the bone marrow before neutrophils reach the lung; by inhibiting DPP1 with brensocatib, the activity of elastase, cathepsin G, and proteinase 3 is reduced, breaking the inflammatory cycle that drives repeated exacerbations in bronchiectasis and offering the first approved disease-modifying approach for this chronic condition.

Insmed differentiates itself through its deep focus on rare pulmonary diseases, with both ARIKAYCE and BRINSUPRI addressing conditions with no previously approved disease-modifying therapies, and its strategy of expanding brensocatib's DPP1 inhibition mechanism into multiple neutrophil-driven inflammatory conditions beyond bronchiectasis.

BRINSUPRI is the first approved DPP1 inhibitor and the first oral disease-modifying treatment for non-cystic fibrosis bronchiectasis, a chronic lung condition affecting hundreds of thousands of patients in major markets who previously had no approved therapy to reduce the frequency of exacerbations and slow disease progression.

Insmed's pipeline is defined by rare pulmonary diseases—MAC lung disease, bronchiectasis, and pulmonary hypertension through TPIP—neutrophil-driven inflammatory conditions including hidradenitis suppurativa, and an emerging neurology portfolio encompassing gene therapy for Duchenne muscular dystrophy and antisense oligonucleotide therapy for ALS.

Insmed is at a critical commercial inflection point, transitioning from a single-product rare disease company to a multi-product organisation with two approved medicines, targeting at least $1 billion in BRINSUPRI revenues in 2026 while investing in a pipeline that spans Phase 1 through Phase 3 across multiple disease areas.

Key watchpoints include the Phase 3 ENCORE trial topline data for ARIKAYCE in MAC lung disease (March–April 2026), Phase 2b CEDAR results for brensocatib in hidradenitis suppurativa (Q2 2026), the pace and uptake of BRINSUPRI launches in the EU and Japan, and Phase 3 programme initiations for TPIP across pulmonary hypertension indications.

Want to Update your Company's Profile?